Exosome Therapy for Livedoid Vasculitis Following COVID-19 Vaccination: A Case Report

Tsung-Kun Lin,1,2,* Chih-Feng Chang,3,* Gwo-Ping Jong4,5 1Department of Pharmacy, Tri-Service General Hospital, Taipei, Taiwan, Republic of China; 2School of Pharmacy, National Defense Medical University, Taipei, Taiwan, Republic of China; 3Division of Cardiology, Department of Internal Medicine, Taichung Armed Force General Hospital, Taichung, Taiwan, Republic of China; 4Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China; 5School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China*These authors contributed equally to this workCorrespondence: Gwo-Ping Jong, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China, Email [email protected]: Livedoid vasculitis is a vascular autoimmune disorder affecting the skin. It most commonly occurs in young women. The occurrence of this condition after the coronavirus 2019 (COVID-19) vaccination is rare. The available literature suggests limited use of exosomes in the treatment of livedoid vasculitis. We present the case of a 65-year-old Chinese man who developed livedoid vasculitis after COVID-19 vaccination. We posit that the etiology in this case may be either COVID-19 vaccine-induced immune stimulation or activation of the condition by a rare vaccine component. This case is unique, with no previously reported precedents. The patient was treated intravenously for 1 month with stem cell-derived exosome therapy, using stem cells derived from exfoliated human deciduous teeth. This resulted in improvement in the livedoid vasculitis, with no reemergence of symptoms. This case highlights the therapeutic benefits of exosome treatment for livedoid vasculitis after COVID-19 vaccination. However, large-scale studies are needed before this outcome can be generalized.Keywords: livedoid vasculitis, COVID-19 vaccination, exosomes, elderly, exfoliated human deciduous teeth

Authors

Publication Details

Journal
DOAJ (DOAJ: Directory of Open Access Journals)
Published
2026-05-01
Primary Topic
Dermatological and COVID-19 studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exosome Therapy for Livedoid Vasculitis Following COVID-19 Vaccination: A Case Report

Jong GP, Lin TK, Chang CF
DOAJ (DOAJ: Directory of Open Access Journals)
Dermatological and COVID-19 studies
article

Exosome Therapy for Livedoid Vasculitis Following COVID-19 Vaccination: A Case Report

Jong GP, Lin TK, Chang CF
article en

Abstract

Tsung-Kun Lin,1,2,* Chih-Feng Chang,3,* Gwo-Ping Jong4,5 1Department of Pharmacy, Tri-Service General Hospital, Taipei, Taiwan, Republic of China; 2School of Pharmacy, National Defense Medical University, Taipei, Taiwan, Republic of China; 3Division of Cardiology, Department of Internal Medicine, Taichung Armed Force General Hospital, Taichung, Taiwan, Republic of China; 4Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China; 5School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China*These authors contributed equally to this workCorrespondence: Gwo-Ping Jong, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China, Email [email protected]: Livedoid vasculitis is a vascular autoimmune disorder affecting the skin. It most commonly occurs in young women. The occurrence of this condition after the coronavirus 2019 (COVID-19) vaccination is rare. The available literature suggests limited use of exosomes in the treatment of livedoid vasculitis. We present the case of a 65-year-old Chinese man who developed livedoid vasculitis after COVID-19 vaccination. We posit that the etiology in this case may be either COVID-19 vaccine-induced immune stimulation or activation of the condition by a rare vaccine component. This case is unique, with no previously reported precedents. The patient was treated intravenously for 1 month with stem cell-derived exosome therapy, using stem cells derived from exfoliated human deciduous teeth. This resulted in improvement in the livedoid vasculitis, with no reemergence of symptoms. This case highlights the therapeutic benefits of exosome treatment for livedoid vasculitis after COVID-19 vaccination. However, large-scale studies are needed before this outcome can be generalized.Keywords: livedoid vasculitis, COVID-19 vaccination, exosomes, elderly, exfoliated human deciduous teeth

DOAJ (DOAJ: Directory of Open Access Journals)
Openalex Percentile: Top 5%
Dermatological and COVID-19 studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Exosome Therapy for Livedoid Vasculitis Following COVID-19 Vaccination: A Case Report — Jong GP, Lin TK, et al. · DOAJ (DOAJ: Directory of Open Access Journals) (2026) | TGRS Research Map | TGRS